Lipid-associated sialoprotein in the cerebrospinal fluid: Association with brain malignancies

Cancer

Volumn 92, Issue 4, 2001, Pages 856-862

  Katopodis, Nonda ^a   Glantz, Michael J ^b   Kim, Lyndon ^c   Dafni, Urania ^d   Wu, Julian K ^e   Perides, George ^e  

^a Oncomedics Inc   (United States)

^b Southwestern Vermont Medical Center   (United States)

^c University of Athens ^*

^d UNIVERSITY OF ATHENS   (Greece)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Brain tumors; Central nervous system metastases; Cerebrospinal fluid; Sialic acid; Tumor marker

Indexed keywords

LIPID; SIALOPROTEIN;

ADULT; ARTICLE; BRAIN CANCER; BRAIN LEVEL; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; TUMOR MARKERS, BIOLOGICAL;

EID: 0035880762     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010815)92:4<856::AID-CNCR1393>3.0.CO;2-9     Document Type: Article

References (40)

1. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel
2. A prospective randomized trial of single-agent versus combination chemotherapy in menigeal carcinomatosis
3. Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the National Cancer Institute experience
4. Treatment of meningeal neoplasms
5. Tumor biology in explanation of the failure of screening for cancer and in determination of future strategies
6. Effective head and neck tumor markers. The continuing quest
7. Tumor markers: Value and limitations in the management of cancer patients
8. Carcinoembryonic antigen
9. Tumor markers in cancer diagnosis and prognosis
10. Lipid-associated sialic acid test for the detection of human cancer
11. Diagnosis and outcome measures in trials for neoplastic meningitis: A review of the literature and clinical experience
12. Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases
13. Cytologically negative carcinomatous meningitis: Usefulness of CSF biochemical markers
14. Cerebrospinal fluid biochemical markers of central nervous system metastases
15. Vascular endothelial growth factor in CSF. A biological marker of carcinomatous meningitis
16. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy
17. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis
18. Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosis
19. Improved method to determine lipid bound sialic acid in plasma or serum
20. A method for judging all contrasts in the analysis of variance
21. Use of ranks on one-criterion variance analysis
22. Cancer statistics
23. Response criteria for phase II studies of supratentorial malignant glioma
24. Diagnostic sensitivity, diagnostic specificity, and predictive value of the determination of tumor markers
25. Assessment of tumor markers in CSF
26. Malignancy markers in the cerebrospinal fluid
27. Total and lipid-bound sialic acid in the cerebrospinal fluid of patients with brain tumors
28. Phase II trials of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
29. Cerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results
30. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives
31. Gangliosides in blood serum of normal rats and Morris hepatoma 5123tc-bearing rats
32. Glycolipid bound sialic acid in serum: Increased levels in mice and humans bearing mammary carcinomas
33. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature
34. Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer patients
35. Comparison of three tumor markers 0CA-125, lipid-associated sialic acid (LSA) and NB/70K- in monitoring ovarian cancer
36. Relationship of serum CA 125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies
37. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advance ovarian cancer